Novartis is a “pure-play” innovative medicines company. We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple ...

New Spherix Global Insights Data Reveals 85% of FSGS Patients Have Actively Progressing Disease Despite Treatment, Underscoring Urgent Demand for Innovative Treatments Findings from Spherix’s ...

The U.S. FDA approved 20 drugs for market in April, slightly down from 22 in March, 16 in February and 12 in January. This brings the total number of FDA approvals for the first four months of 2025 to ...

Vanrafia is an endothelin receptor antagonist. Here's how it treats immunoglobulin A nephropathy.

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease.

This commitment is reflected in three FDA approvals in renal care within nine months, including Vanrafia® in IgA nephropathy (IgAN) in April 2025, and Fabhalta® for C3 glomerulopathy (C3G) and IgAN in ...

The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core operating income set to grow by low double-digits.View on euronews ...

VANRAFIA (atrasentan), FDA-approved in April 2025, showed strong proteinuria reduction without REMS but carries similar safety warnings, requiring ongoing liver and pregnancy monitoring. However ...

VANRAFIA (atrasentan), FDA-approved in April 2025, showed strong proteinuria reduction without REMS but carries similar safety warnings, requiring ongoing liver and pregnancy monitoring. However ...